The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Similar Adherence Rates Favor Different Virologic Outcomes for Patients Treated with Nonnucleoside Analogues or Protease Inhibitors
Abstract
BACKGROUND: This prospective study verified the effect of adherence on the risk of virologic failure. METHODS: At enrollment in the study, a total of 543 patients who were following a steady (duration, >or=6 months) and effective (viral load, <50 human immunodeficiency virus [HIV] RNA copies/mL) regimen of highly active antiretroviral therapy (HAART) completed a self-reported questionnaire derived from the Adult AIDS Clinical Trials Group Adherence Follow-up Questionnaire. Patients were followed up for the subsequent 6 months to document virologic failure, which was defined as 2 consecutive viral load measurements of >500 HIV RNA copies/mL. RESULTS: Only the type of treatment and the adherence rate at baseline were significantly associated with the virologic end point. Among patients who reported an adherence rate of 95%. When analysis was adjusted according to the type of regimen received, patients who were receiving protease inhibitor (PI)-based HAART and who had an adherence rate of up to 85% had a virologic failure rate of >20%, whereas, only for patients who were receiving nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based HAART and who had an adherence rate of 10%. For the comparison of NNRTI-treated patients and PI-treated patients with an adherence rate of 75%-95%, the odds ratio was 0.157 (95% confidence interval, 0.029-0.852). The number of pills and daily doses received correlated with the reported adherence rate. CONCLUSIONS: Patients receiving NNRTIs report a higher rate of adherence than do patients receiving PIs. Adherence is significantly influenced by the number of pills and daily doses received. Low adherence is a major determinant of virologic failure; however, different therapies have different cutoff values for adherence that determine a significant increment of risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., Wu, A. W., & PATIENT CARE COMMITTEE & ADHERENCE (2000) · AIDS Care · doi:10.1080/09540120050042891 · Cited by 1,428
Cited by
Bangsberg, D. R. (2006) · Clinical Infectious Diseases · doi:10.1086/507526 · Cited by 534
Adherence to Nonnucleoside Reverse Transcriptase Inhibitor–Based HIV Therapy and Virologic Outcomes
Nachega, J. B., Hislop, M., Dowdy, D. W., Chaisson, R. E., Regensberg, L., & Maartens, G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00007 · Cited by 374
Usach, I., Melis, V., & Peris, J. (2013) · Journal of the International AIDS Society · doi:10.7448/ias.16.1.18567 · Cited by 373
Lima, V. D., Harrigan, R., Bangsberg, D. R., Hogg, R. S., Gross, R., Yip, B., & Montaner, J. S. G. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31819675e9 · Cited by 304
HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving Concepts
B. Nachega, J., C. Marconi, V., U. van Zyl, G., M. Gardner, E., Preiser, W., Y. Hong, S., J. Mills, E., & Gross, R. (2011) · Infectious Disorders - Drug Targets · doi:10.2174/187152611795589663 · Cited by 271
Oyugi, J. H., Byakika-Tusiime, J., Ragland, K., Laeyendecker, O., Mugerwa, R., Kityo, C., Mugyenyi, P., Quinn, T. C., & Bangsberg, D. R. (2007) · AIDS · doi:10.1097/qad.0b013e32802e6bfa · Cited by 263
Preventing HIV Antiretroviral Resistance through Better Monitoring of Treatment Adherence
Bangsberg, D. R. (2008) · The Journal of Infectious Diseases · doi:10.1086/533415 · Cited by 183
Chung, M. H., Richardson, B. A., Tapia, K., Benki-Nugent, S., Kiarie, J. N., Simoni, J. M., Overbaugh, J., Attwa, M., & John-Stewart, G. C. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000422 · Cited by 109
Healthcare Costs Associated with Antiretroviral Adherence Among Medicaid Patients
Pruitt, Z., Robst, J., Langland-Orban, B., & Brooks, R. G. (2015) · Applied Health Economics and Health Policy · doi:10.1007/s40258-014-0138-1 · Cited by 11
Metadata
- Authors
- Maggiolo, F., Ravasio, L., Ripamonti, D., Gregis, G., Quinzan, G., Arici, C., Airoldi, M., & Suter, F.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-01-01
- Volume
- 40
- Issue
- 1
- Pages
- 158-163
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2167877735
- Cited by
- 224
- References
- 1
- FWCI
- 9.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.